Developed in partnership with Zylö Therapeutics, Hoth’s AEA-loaded Z-pods™ are currently being tested for approval in the treatment of Cutaneous Lupus Erythematosus (CLE). Read more >>
Hoth Therapeutics, Inc., a biopharmaceutical company, today announced it has completed a strategic investment in Zylö Therapeutics, Inc. Mr. Robb Knie, Chief Executive Officer of Hoth, commented, “We are pleased to expand our partnership with Zylö and look forward to working together as our therapeutic for Lupus patients continues through the next phase of development. Read more >>
Hoth Therapeutics, Inc., a biopharmaceutical company, today announced top line data from its Cutaneous Lupus Erythematosus (CLE) study, a chronic autoimmune skin disease, in partnership with Zylö Therapeutics, Inc. for topical administration of Anandamide (AEA)-loaded Z-pods™. Read more >>
The study conducted in partnership with Zylö Therapeutics confirmed AEA-loaded in Z-pods™ provides an actual reduction in lesion score. Read more >>
One of the few venture funds making investments in South Carolina reported another record year in 2019, scaling up its capital outlays by 82 percent from 2018. VentureSouth, which is based in Greenville and has local chapters, focuses on promising companies in the Southeast, including Zylo Therapeutics. Read more >>
”
Hoth Therapeutics, Inc….today announced initiating a confirmatory study, related to their proprietary AEA-loaded Z-pods in the treatment of Cutaneous Lupus Erythematosus [CLE], a chronic autoimmune disease that affects the skin. The study is being conducted in partnership with Zylo Therapeutics to confirm that topical administration of Hoth’s AEA-loaded Z-pods inhibits the development of CLE lesions in a well-established animal model of lupus. Read more >>
Zylö Therapeutics Inc., developer of the transformational Z-pod™ topical delivery platform, has been awarded a $225,000 Small Business Technology Transfer grant. The grant was sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (a division of the NIH) to further develop Zylö’s proprietary nitric-oxide topical delivery system (called Z-pods™); and the project is titled, “Optimization of microparticle-based topical treatments for treating erectile dysfunction in patients refractory to oral PDE5 inhibitors.” Read more >>
The study is being conducted in partnership with Zylö Therapeutics to confirm that topical administration of Hoth’s AEA-loaded Z-pods™ inhibits the development of CLE lesions in a well-established animal model of lupus. Test protocol requires weekly scoring and a treatment period of 10 weeks after the initial lesions are recorded. Read more >>
Zylö Therapeutics Inc., developer of the transformational Z-pod™ topical delivery platform, announced that its scientific advisor, Adam Friedman MD, will serve as a keynote speaker at the Dermatology Update 2019 Fall Meeting in Toronto on November 7. Read more >>
Zylö Therapeutics Inc., dedicated to developing a transformational topical delivery platform, announced that on September 21, 2019, it effected a closing of its Series A financing through the sale of $4 million of Series A preferred shares. Read more >>
